A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI 906 Plus Erlotinib (Tarceva), or Erlotinib Plus Placebo in Patients With Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC

Trial Profile

A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI 906 Plus Erlotinib (Tarceva), or Erlotinib Plus Placebo in Patients With Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Linsitinib (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 03 Aug 2017 Primary endpoint (The Progression Free Survival (PFS) of maintenance OSI-906 plus erlotinib vs placebo plus erlotinib) has not been met as per the results published in the British Journal of Cancer.
    • 03 Aug 2017 Results published in the British Journal of Cancer
    • 28 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top